Latest Serum amyloid P component Stories
The deposition of amyloid beta in the brain of individuals with Alzheimer's disease is the focus of much research into both its cause and treatment.
British researchers have developed a new drug against Alzheimer's disease they say has shown promise in tests on a handful of patients.
New therapeutic approaches in Alzheimer's disease are urgently needed. Work led by Professor Mark Pepys FRS over more than 20 years has identified a protein known as serum amyloid P component (SAP) as a possible therapeutic target in Alzheimer's disease.